Home
 
Companies
 
Patients
 
Investigators
 
Trials & Research
 
Regulatory
 
Therapeutics
News
Features
Commentary
People
Events
White Papers
Home - Commentary
Renal Failure: challenges and opportunities
10 March 2010
The term renal failure describes a decline in the excretory function of the kidney due to a reduction in glomerular filtration rate. In adults, renal failure may be either acute, lasting from a few days to a few weeks, or chronic, lasting months to years. Acute renal failure is a medical ...
Filling the gaps
01 March 2010
Most stakeholders in Europe are in favour of some form of EU centralised approval system for multinational clinical trials, with the pharmaceutical industry and the European Medicines Agency among the strongest backers for such a move. But the support is not unanimous: many national regulatory ...
The fight against malaria - all still to play for
02 February 2010
If you didn't know, how many cases of malaria would you guess occur every year around the globe? A million? Two million? In fact, around 250 million cases of malaria occur each year. Most of these occur in developing countries, although malaria is also an issue for travellers from developed ...
UK wants harmonisation, not centralisation, of European trial approvals
21 January 2010
The UK drug regulator, the MHRA, says it does not want a centralised approvals system for clinical trials in Europe, preferring instead the voluntary harmonisation project for authorising multinational studies that is currently being piloted in the EU. The MHRA also feels that introducing a single ...
EU promises multinational CTA harmonisation at last
08 January 2010
The problem stems mainly from the way that the EU clinical trials Directive (2001/20/EC) has been implemented by the various member states. National authorities have different format, language and content requirements for clinical trial approvals, as well as different timelines for reviewing ...
Search continues for improved BPH treatments
04 January 2010
The recent announcement by Boehringer Ingelheim that it plans to make the alpha blocker tamsulosin available without a prescription in the UK is a reflection of the continued interest in the benign prostatic hyperplasia (BPH) market. The condition affects some 15 million men across the seven major ...
 
 
COMPANY/ORGANISATION
 
CONDITION
 
GEOGRAPHY
 
DRUG
 
 
About Us
Getting Started
Subscribe
FREE Trial
Advertise
Awards
White Papers
EVENTS
Designing the Future Conditions for Clinical Research in Europe
17 March 2010
Brussels, Belgium
ICR Annual Spring Conference and Exhibition
19 April 2010
London, UK
CDISC Interchange Europe
26 April 2010
London, UK
 
Home
General
Companies
Patients
News Features Analysis Commentary People Events
About Us Advertise Site Map Privacy Policy Terms & Conditions Subscribe
  Investigators   Trials & Research
  Regulatory   Therapeutics
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36